Touting CD161 as a test case for single-cell tech, Longwood-backed Immunitas bags $58M for next-gen I/O work

Back when Longwood unveiled its latest immunotherapy startup, Immunitas, the VC’s co-founder Lea Hachigian talked at length about how its single-cell genomics analysis platform could enable researchers to “ask questions of the immune system we weren’t able to ask before,” understand human biology on a much deeper level and identify...

Click to view original post